Cidara Therapeutics: $11.1M European Approval Milestone

Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma for European Approval of New Antifungal Drug

Biotechnology company Cidara Therapeutics has announced that it has received a significant $11.1 million milestone payment from Mundipharma. This payment follows the European approval of Cidara’s latest product, Rezzayo (rezafungin acetate).